Dr Philip Mease shares his clinical insights for diagnosing and treating fibromyalgia and psoriatic arthritis.
Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.
The therapeutic landscape for polymyalgia rheumatica (PMR) has grown and will grow further, allowing prolonged use of glucocorticoids (GCs) to be minimized, Anisha B. Dua, MD, MPH, of Feinberg School ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results